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Abstract
Background: Among HIV-infected persons initiating highly active antiretroviral therapy (HAART), early CD4+
lymphocyte count increases are well described. However, whether CD4+ levels continue to increase or plateau
after 4-6 years is controversial.
Methods: To address this question and identify other determinants of CD4+ response, we analyzed data for 1,846
persons from a prospective HIV military cohort study who initiated HAART, who had post-HAART CD4+
measurements, and for whom HIV seroconversion (SC) date was estimated.
Results: CD4+ count at HAART initiation was ≤ 200 cells/mm
3 for 23%, 201-349 for 31%, 350-499 for 27%, and
≥500 for 19%. The first 6 months post-HAART, the greatest CD4+ increases (93-151 cells) occurred, with lesser
increases (22-36 cells/year) through the first four years. Although CD4+ changes for the entire cohort were
relatively flat thereafter, HIV viral load (VL) suppressors showed continued increases of 12-16 cells/year. In
multivariate analysis adjusting for baseline CD4+ and post-HAART time interval, CD4+ responses were poorer in
those with: longer time from HIV SC to HAART start, lower pre-HAART CD4+ nadir, higher pre-HAART VL, and
clinical AIDS before HAART (P < 0.05).
Conclusions: Small but positive long-term increases in CD4+ count in virally suppressed patients were observed.
CD4+ response to HAART is influenced by multiple factors including duration of preceding HIV infection, and
optimized if treatment is started with virally suppressive therapy as early as possible.
Background
Among those with human immunodeficiency virus
(HIV) infection, the CD4+ T-lymphocyte count is the
major indicator of immunodeficiency, a main factor in
deciding whether to initiate highly active antiretroviral
therapy (HAART), and an important parameter in mon-
itoring treatment response [1,2]. Failure to restore a
normal CD4+ count following HAART is associated
with increased morbidity due to both AIDS and non-
AIDS events, as well as increased mortality [3-5].
Studies of the kinetics of CD4+ count response post-
HAART indicate that the CD4+ count increases rapidly
during the first 3-6 months, in part due to release of
m e m o r yT - c e l l sf r o ml y m p h o i dt i s s u e ,a n dt h e n
increases slowly during the next 3-4 years, reflecting
reconstitution of the immune system [6-10]. The magni-
tude of CD4+ recovery may depend on a variety of fac-
tors, including maintenance of virologic suppression,
age, and CD4+ count at HAART initiation [1,7,9,11-20].
The question of whether those initiating HAART will
continue to increase their CD4+ count after 4-5 years or
will plateau has been debated in the literature, and
remains unclear. Some studies have suggested that nor-
malization of CD4+ counts in HIV-infected persons can
be achieved if viral suppression with HAART can be
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any medium, provided the original work is properly cited.maintained for a sufficiently long period of time [19]. In
one study, after > 5 years on HAART, patients with
viral suppression who started at ≤200 cells/mm
3 had an
adjusted annual increase of 32 cells/mm
3, attaining an
average CD4+ count of 497 cells/mm
3 [19]. Another
study statistically estimating the CD4+ trajectory con-
cluded that those starting HAART at ≤200 CD4+ cells
who remained on therapy would continue to increase
through 7 years, although 25% still had ≤350 cells at
7 years [20]. One small study of 16 patients followed for
up to 10 years with strict viral control based on HIV
RNA detection using ultrasensitive techniques showed
continued positive increases in CD4+ counts, although
t h i ss t u d yr e p r e s e n t e das m a l lg r o u po fh i g h l ys e l e c t e d
patients [21]
On the other hand, other studies report that the aver-
age CD4+ count may level off after 4-6 years following
HAART initiation, even among patients with viral sup-
pression [12,13]. Given this leveling off, many patients
who start at lower CD4+ counts, even after years on
HAART with early CD4+ increases, may fail to reach a
normal CD4+ threshold. In one study of those with sus-
tained viral suppression who started HAART at ≤200
CD4+ cells/mm
3, after 6 years only 42% had ≥ 500
CD4+ cells/mm
3, and only 12% had >750 cells/mm
3
[12]. In another study, 44% of those starting therapy
with a CD4+ count <100 cells/mm
3 and 25% of those
starting HAART with a CD4+ count of 100-200 cells were
unable to achieve a CD4+ cell count >500 cells/mm
3 over
a mean follow-up of seven years, and many did not reach
this threshold by year 10 [18].
The important question of the long-term CD4+ count
response therefore remains unresolved. This question is
especially relevant for those who start HAART at lower
CD4+ counts. Despite current recommendations to start
HAART at CD4+ counts of 350 cells/mm
3 or greater
[1,2], the reality is that many patients, even in developed
countries, are still being diagnosed and initiate treat-
ment late in the course of their HIV infection [22,23].
An additional methodological challenge in using
observational data to evaluate the long-term effect of
CD4+ count at HAART initiation on subsequent
response is that those starting HAART at lower CD4+
levels may have been infected for longer periods of time.
If the post-HAART response is affected by duration of
HIV infection, comparing different strata without
accounting for the fact that those initiating HAART at
lower CD4+ levels may have a longer lead-time can
result in biased group comparisons [24].
We were able to address both of these issues by ana-
lyzing data from the U.S. Military HIV Natural History
Study (NHS) [25]. This prospective cohort of HIV-
infected U.S. military personnel has followed some parti-
cipants for up to twelve years after availability of
HAART. Because all active duty personnel are con-
firmed to be HIV-negative prior to enlistment and
undergo routine HIV screening, HIV seroconversion
(SC) date can be reliably determined for the majority of
members. All cohort members have free access to care
and availability of therapy. Data from this cohort were
analyzed to determine the long-term CD4+ count trajec-
tory after HAART initiation, as well as the influence of
baseline CD4+ count, duration of HIV infection, and
other covariates on post-HAART CD4+ response.
Methods
Study Cohort and Data Elements
The NHS is an observational prospective cohort study of
consenting U.S. military personnel and beneficiaries
[25]. Since 1985, routine HIV testing has been used to
restrict HIV-infected persons from enlistment. Active
duty personnel undergo repeat HIV screening every 1-5
years. Those found HIV-positive after enlistment, plus
HIV-positive retirees and dependents of active duty per-
sonnel, receive free medical evaluation and ongoing care
at military medical centers. Although HIV transmission
risk groups are not routinely assessed, injection drug
use was not self-reported by any Navy or Marine per-
sonnel who seroconverted for HIV during 1997-8 [26].
More recently, hepatitis C prevalence of only 3% was
reported for evaluable subjects in this cohort [27], con-
sistent with low injection drug use.
Since 1986, the NHS has enrolled 5,091 HIV-positive
participants; NHS protocol is for patients to be seen
every six months at one of seven participating military
medical centers. Data collected include demographics,
medical histories including medication use, and labora-
tory measures including CD4+ count. In 1996, HIV viral
load (VL) became available to the study.
This analysis was limited to those with: (1) documen-
ted HIV-positive status, (2) HAART receipt after July 1,
1995, with a documented HAART initiation date, (3) a
CD4+ count within six months before HAART initiation
and (4) at least one follow-up CD4+ count after
HAART. Because they represented a distinct population,
dependents of active duty personnel were not included
in this analysis. Data were evaluated through February
2010.
This substudy was approved by the governing central
institutional review board. The study was conducted
according to the principles expressed in the Declaration
of Helsinki. All study participants in the NHS provided
written informed consent
Statistical Analysis
Of 1846 patients in this analysis, 1475 (80%) had docu-
mented last negative and first positive HIV test dates,
with the estimated HIV SC date calculated as the
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Page 2 of 11mid-point. For 371 (20%) patients, the date of the first
positive but not the last negative HIV test was recorded
in the study’s database; the estimated SC date for these
patients was imputed based upon the median time
between the first positive and last negative dates for
other cohort members with known and comparable first
HIV positive test dates.
Baseline CD4+ count and VL were taken as the values
most closely preceding the HAART initiation date
within the prior 6 months. For CD4+ response curves,
every six-month values were chosen based on the CD4+
count whose date most closely approximated intervals
of six month follow-up from HAART initiation; CD4+
counts had to be obtained within a 3 month window of
the interval date. CD4+ follow-up time was truncated at
the earliest of the following: last recorded visit at which
a CD4+ count was obtained; last recorded visit prior to
three successive 6-month visits with missing CD4+
counts; death; or 12-year post-HAART visit.
Visual inspection of the post-HAART CD4+ response
curve for all patients indicated that the CD4+ response
curves were not simple linear slopes. Based on our
inspection, breakpoints of 0.5 and 4.0 years post-
HAART were assigned, and linear mixed effects models
with splines were used to model separate CD4+ slopes
for the following time periods after HAART initiation: 0
to 0.5 years; 0.5 to 4 years; and > 4 years. Random
effects for intercepts and slopes were included.
Separate CD4+ response curves were generated for
those initiating HAART at CD4+ “baseline” counts of
≤200, 201-349, 350-499, and ≥500 cells/mm
3. Interac-
tions between post-HAART time period and baseline
CD4+ strata were included in linear mixed effects mod-
els to estimate and compare separate CD4+ slopes by
baseline CD4+ group. Baseline characteristics between
CD4+ strata were compared using chi-square tests or
analysis of variance.
Unadjusted models first compared CD4+ response tra-
jectories between the four baseline strata; multivariate
models then compared baseline CD4+ strata adjusting
for the following covariates: age at HAART start, gen-
der, race/ethnicity, presence of clinical AIDS prior to
HAART, baseline VL (most closely prior to HAART
start), any ART prior to HAART, time from estimated
HIV SC date to HAART initiation date, year of HAART
start, and nadir pre-HAART CD4+ count. Clinical AIDS
was defined as presence of a clinical disease (not CD4+
count) meeting the 1993 Centers for Disease Control
AIDS case definition [28]. As previously defined for the
NHS [29], HAART included ART regimens with drugs
from two or more classes, or certain combinations of
three or more nucleoside/nucleotide reverse transcrip-
tase inhibitors (NRTI); patients on ART not meeting the
HAART definition were typically on mono or dual
NRTI regimens. Age was modeled as a linear spline to
allow for separate linear estimates among those < 40
years and among those ≥40 years. Holm’ss t e p d o w n
Bonferroni method adjusted for multiple slope
comparisons.
This analysis was repeated for the subset of partici-
pants defined as VL suppressors. Because VL assays
with different detection limits were used during follow-
up, an undetectable VL was defined as <400 copies/ml.
VL suppression was defined as two consecutive unde-
tectable VLs, with the first within 48 weeks after
HAART start. Data for this subgroup were censored
when two consecutive VL measurements ≥400 copies/
ml were first observed.
To evaluate robustness of our main findings, additional
exploratory models were constructed with additional vari-
ables added as covariates. In the first model, a time-
updated variable was added to indicate whether the patient
was on or off HAART at each 6-month follow-up visit. In
the second model, time-updated log10-transformed VL
(based on six-month post-HAART values) was added; the
separate baseline VL covariate was removed since it is cap-
tured in the time-updated covariate. In the third model,
initial HAART regimen was added, and categorized
as NRTI plus protease inhibitor (PI), NRTIs plus non-
nucleoside reverse transcriptase inhibitor (NNRTI), NRTIs
alone, and regimens with both NNRTIs and PIs.
Results
Characteristics at HAART initiation
One thousand eight hundred and forty-six HIV-positive
individuals met analysis inclusion criteria, with charac-
teristics summarized in Table 1. The median length of
follow-up post-HAART was 5.5 years, and median num-
ber of CD4+ count values obtained post-HAART (using
six-month intervals) was 10 (interquartile range: 4, 18).
C D 4 +c o u n ta tH A A R Ti n i t i a t i o nw a s≤ 200 cells/
mm
3 for 23% of participants, 201-349 cells for 31%,
350-499 cells for 27%, and ≥500 cells for 19%. The four
strata differed significantly by multiple characteristics
(Table 1). Among other differences, AIDS prior to
HAART, baseline VL ≥100,000 copies/ml, and longer
time from SC to HAART start were all most common
in those with a baseline CD4+ ≤200 cells/mm
3.
CD4+ response curves after HAART initiation
Figure 1 shows the CD4+ count response after HAART
initiation for all participants in this analysis. For the first
6 months after HAART initiation, the average increase
in CD4+ count was 129.9 cells (95% CI 122.0, 137.8).
For the second phase (0.5-4.0 years) after HAART, the
average annual increase was 29.1 cells (95% CI 24.5,
33.7). For the third phase (4.0-12.0 years), the average
annual change was -0.4 cells (95% CI -4.5, +3.6).
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HAART initiation by baseline CD4+ stratum. The mean
CD4+ cell count at 4, 8, and 12 years post-HAART was
324, 367 and 402 (95% CI: 356, 448) for the ≤200 CD4+
cell baseline stratum; 532, 513 and 548 (95% CI: 478,
618) for the 201-349 cell stratum; 641, 611 and 666
(95% CI: 602, 729) for the 350-499 cell stratum; and
846, 799 and 814 (95% CI: 684, 945) for the ≥500 cell
stratum.
The average CD4+ change and 95% CI for each of the
t h r e ep o s t - H A A R Tt i m ei n t e r v a l sa r es u m m a r i z e di n
Table 2; the first time period is presented as CD4+
change per half-year; the second and third time periods
present CD4+ change per year. Within all CD4+ strata,
the greatest average increases (93-151 cells) were noted
Table 1 Characteristics of Participants in U.S. Military HIV Natural History Study by Baseline CD4+ Strata at HAART
Initiation
CD4+ (cells/mm
3) at HAART start
≤200 201-349 350-499 ≥500 Total
(N = 419) (N = 580) (N = 493) (N = 354) (N = 1846)
Male 397 (95%) 566 (98%) 470 (95%) 337 (95%) 1770 (96%)
Race/ethnicity
Caucasian 169 (40%) 255 (44%) 216 (44%) 172 (49%) 812 (44%)
African American 199 (47%) 246 (42%) 211 (43%) 139 (39%) 795 (43%)
Hispanic 38 (9%) 54 (9%) 49 (10%) 27 (8%) 168 (9%)
Other 13 (3%) 25 (4%) 17 (3%) 16 (5%) 71 (4%)
Year of HAART start *
1995-1999 311 (74%) 289 (50%) 298 (60%) 245 (69%) 1143 (62%)
2000-2003 43 (10%) 104 (18%) 97 (20%) 68 (19%) 312 (17%)
2004-2008 65 (16%) 187 (32%) 98 (20%) 41 (12%) 391 (21%)
Median age at
HAART start (IQR) * 36 (31, 42) 34 (29, 39) 34 (28, 39) 34 (29, 39) 34 (29, 40)
CD4+ nadir (cells/mm
3)*
≤200 419 (100%) 83 (15%) 20 (4%) 10 (3%) 532 (29%)
201-349 0 (0%) 497 (86%) 180 (37%) 58 (16%) 735 (40%)
350-499 0 (0%) 0 (0%) 293 (59%) 96 (27%) 389 (21%)
≥500 0 (0%) 0 (0%) 0 (0%) 190 (54%) 190 (10%)
Baseline VL at HAART start (copies/ml) *
<1000 17 (4%) 37 (6%) 59 (12%) 65 (18%) 178 (10%)
1,000-9,999 25 (6%) 111 (19%) 107 (22%) 92 (26%) 335 (18%)
10,000-99,999 156 (37%) 290 (50%) 231 (47%) 131 (37%) 808 (44%)
≥100,000 170 (41%) 117 (20%) 72 (15%) 54 (15%) 413 (22%)
Missing 51 (12%) 25 (4%) 24 (5%) 12 (3%) 112 (6%)
AIDS diagnosis prior to
HAART * 116 (28%) 24 (4%) 19 (4%) 7 (2%) 166 (9%)
On ART prior to HAART * 277 (66%) 217 (37%) 221 (45%) 146 (41%) 861 (47%)
Median years HIV SC to
HAART start (IQR) * 6.8 (3.5,10.1) 3.2 (1.3,7.3) 3.3 (1.4,7.2) 2.8 (1.0,7.2) 4.1 (1.4,8.4)
Median years post-HAART
follow-up (IQR) ** 4.9 (2.2,11.4) 4.5 (2.0,9.2) 6.0 (2.1,10.8) 6.1 (2.6,10.6) 5.5 (2.1, 10.5)
* P < 0.001 **P = 0.001.
HAART = Highly active antiretroviral therapy; ART = Antiretroviral therapy;
VL = HIV Viral load; IQR = Interquartile range; SC = Seroconversion.
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Figure 1 CD4+ Response Curve After HAART Initiation for All
Participants, U.S. Military HIV Natural History Study.
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Figure 2 CD4+ Response Curve After HAART by CD4+ Strata at HAART Initiation for All Participants, U.S. Military HIV Natural History
Study.
Table 2 Average Change in CD4+ Count by Time Since HAART Initiation: All Participants and Viral Suppressors in U.S.
Military HIV Natural History Study
CD4+ strata Estimated CD4+ count change and 95% CI (cells/mm
3) by time segment (Years from HAART initiation)
at HAART start 0-0.5 yrs 0.5-4.0 yrs >4.0 yrs
(change/half-year) (change/year) (change/year)
≤200 cells/mm
3
All participants 109 (93, 126) 36 (30, 43) 8.6 (3.3, 14.0)
Viral suppressors 147 (123, 172) 66 (56, 75) 13.6 (6.0, 21.2)
201-349 cells/mm
3
All participants 149 (135, 162) 34 (28, 39) 3.5 (-1.3, 8.4)
Viral suppressors 171 (155, 188) 54 (48, 60) 14.4 (8.5, 20.4)
350-499 cells/mm
3
All participants 151 (136, 166) 22 (16, 28) 1.5 (-3.4, 6.4)
Viral suppressors 177 (159, 195) 51 (44, 57) 12.0 (6.1, 17.8)
≥500 cells/mm
3
All participants 93 (75, 110) 24 (17, 30) -8.1 (-13.9, -2.4)
Viral suppressors 119 (98, 139) 56 (48, 63) 16.2 (9.8, 22.6)
* Significant (P < 0.05) differences in first-phase slopes: (1) All participants: ≤200 vs. 201-349; <200 vs. 350-499; 201-349 vs. ≥500; 350-499 vs. ≥500; (2) VL
suppressors: 201-349 vs. ≥500; 350-499 vs. ≥500;
** Significant (P < 0.05) differences in second-phase slopes: (1) All participants: ≤200 vs. 350-499; (2) VL suppressors: None;
*** Significant (P < 0.05) differences in third-phase slopes: (1) All participants: ≤200 vs. ≥500; 201-349 vs. ≥500; 2) VL suppressors: None.
(All P-values calculated with multiple comparisons adjustment).
HAART = Highly active antiretroviral therapy; CI = Confidence Interval.
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tinued but lesser increases of 22-36 cells/year were
noted during the second-phase period of 0.5-4.0 years
after HAART initiation. During the third phase (>4.0
years post-HAART start), the average CD4+ count
increased slightly (9 cells/year) in the lowest baseline
CD4+ stratum, remained essentially unchanged in
the two middle baseline strata, and decreased slightly
(8 cells/year) in the highest stratum (P < 0.05).
Multivariate analysis and adjusted CD4+ slopes
In a model controlling for baseline CD4+ count and
time interval after HAART start (first-, second- or third-
phase), a number of other variables were significantly
(P < 0.05) associated with CD4+ response (Table 3). A
significantly smaller CD4+ response post-HAART
occurred in those with clinical AIDS prior to HAART, a
lower CD4+ nadir, a higher baseline VL, a greater num-
ber of years from HIV SC to HAART start, Hispanic
ethnicity, and HAART initiation during 2000-2003 (vs.
2004-2009). Any ART prior to HAART was of border-
line significance (P = 0.07).
The numerical estimates listed in Table 3 for different
levels of a specific covariate represent what the differ-
ence in post-HAART CD4+ counts would be after
adjustment for all other covariates in the model. For
example, after adjustment for all other covariates, a
patient with a baseline VL of < 1000 copies/ml will on
average have a post-HAART CD4+ count that is 57.2
cells higher than a patient with a baseline VL of ≥
100,000 copies/ml (the referent). After adjustment, a
patient infected for >8.5 years will on average have a
post-HAART CD4+ count that is 50.6 cells lower than a
patient infected for ≤1.5 years before HAART.
CD4+ response curves for viral suppressors
One thousand one hundred seventy-one participants
met criteria for VL suppressors. Figure 3 shows post-
HAART CD4+ count responses stratified by CD4+
count at HAART initiation for VL suppressors. The
mean CD4+ cell counts at 4, 8, and 12 years post-
HAART for VL suppressors were 448, 517 and 546
(95% CI: 405, 687) for the ≤200 CD4+ cell baseline stra-
tum; 622, 680 and 737 (95% CI: 561, 914) for the 201-
349 CD4+ stratum; 745, 770 and 907 (95% CI: 791,
1023) for the 350-499 CD4+ stratum; and 947, 1006 and
1075 (95% CI: 820, 1330) for the ≥500 CD4+ cell
stratum.
The average CD4+ change and 95% CI for each of the
three post-HAART time intervals for VL suppressors
are summarized in Table 2. The greatest changes were
again noted within the first 6 months, followed by the
0.5-4.0 year period. For the third phase (>4.0 years)
post-HAART, there were significant annual increase in
all baseline strata, although only at a mean of 12-16
cells per year. Second and third phase slopes did not
significantly differ for any of the baseline CD4+ strata
Multivariate analysis for VL suppressors
In multivariate analysis for viral suppressors, factors sig-
nificantly (P < 0.05) associated with a lesser CD4+
response include male sex, lower CD4+ nadir, and
greater time from HIV SC to HAART start (Table 4).
Clinical AIDS before HAART was of borderline signifi-
cance (P = 0.057). Numerical estimates in Table 4 for
Table 3 Adjusted Covariate Estimates * for CD4+ Cell
Response Post-HAART for All Participants, U.S. Military
HIV Natural History Study
Covariate Estimate
(95% CI)
P-
value
Age at HAART start
Effect of 10 years older if < 40 years
old
4.3 (-9.3, 17.9) 0.54
Effect of 10 years older if > 40 years
old
- 7.7 (-23.3, 7.9) 0.34
Female (vs. Male) 23.0 (-8.8, 54.8) 0.16
Race
Caucasian Reference
African American -7.4 (-20.5, 5.7) 0.27
Hispanic -35.0 (-57.8, -12.2) 0.003
Other -0.7 (-35.4, 33.9) 0.97
Clinical AIDS event prior to HAART start -23.3 (-46.1, -0.5) 0.045
Pre -HAART nadir CD4+ count (cells/mm
3)
≤ 200 Reference
201-349 57.2 (31.4, 83.0) <.001
350-499 160.8 (129.2,
192.5)
<.001
≥ 500 236.5 (196.4,
276.6)
<.001
Baseline VL at HAART start (copies/ml) **
< 1000 57.2 (32.5, 81.8) <.001
1000-9999 40.2 (19.5, 60.8) <.001
10,000-99,999 14.4 (-2.5, 31.3) 0.10
≥ 100,000 Reference
Years from SC to HAART initiation
≤ 1.5 Reference
> 1.5 to 4.0 -28.3 (-47.8, -8.8) 0.005
> 4.0 to 8.5 -44.1 (-65.3, -23.0) <.001
> 8.5 -50.6 (-73.4, -27.9) <.001
Year of HAART initiation
1995-1999 -12.8 (-36.6, 10.9) 0.29
2000-2003 -34.4 (-60.3, -8.4) 0.01
2004-2009 Reference
Any ART prior to HAART start -16.4 (-34.4, 1.6) 0.07
* Aside from baseline CD4+ count and time interval after HAART start.
** Analysis adjusted for those for whom VL was missing/unknown.
HAART = Highly active antiretroviral therapy; ART = Antiretroviral therapy;
VL = HIV Viral load; SC = Seroconversion;
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w h a tt h ed i f f e r e n c ei np o s t - H A A R TC D 4 +c o u n t s
would be after adjustment for all other covariates in the
model. For example, after adjustment, a viral suppressor
infected for >8.5 years will on average have a post-
HAART CD4+ count that is 33.4 cells lower than a
patient infected for ≤1.5 years before HAART.
Additional exploratory analyses
In the first model, the time-updated indicator of
HAART use was a significant positive predictor of
CD4+ response (coefficient = 95.1, 95% CI: 87.8, 102.4,
P < 0.001). All significant covariates in the original
adjusted model remained so, except for clinical AIDS
prior to HAART, which was of borderline significance
(P = 0.055). In the second model, time-updated VL after
HAART start was a significant predictor of CD4+
response (coefficient = -42.6 for every log10 increase in
VL, P < 0.001). All significant covariates in the original
adjusted model remained so, except for year of HAART
initiation. In the third model initial HAART regimen
was added to the model. All significant covariates in the
original adjusted model remained so.
Discussion
Among HIV-positive persons starting HAART, we iden-
tified a rapid average increase of 93-151 cells during the
first six months in all baseline CD4+ strata, followed by
a continued average increase of 22-36 cells per year
through the first four years. Among VL suppressors,
these increases were even greater, with an average of
119-177 cells during the first phase, followed by an aver-
age of 51-66 cells per year during the second phase,
through 4 years. For example, a patient who starts
HAART with a CD4+ count of 125 cells/mm
3 and who
maintains viral suppression will on average have an
increase to about 500 cells/mm
3 at the end of four
years.
Am a j o rp u r p o s eo ft h i sa n a l y s i sw a st oi d e n t i f y
whether after four years the CD4+ response continues
to increase or plateaus. Among all participants, the aver-
age third-phase response was slightly positive (8.6 cells/
year) in the lowest CD4+ baseline strata (≤200 cells),
slightly negative (-8.1 cells/year) in the highest strata
(≥500 cells), and essentially flat (with 95% CI overlap-
ping zero) in the two middle strata. However, among
VL suppressors, we identified positive average increases
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Page 7 of 11of approximately 12-16 cells/year, with no significant
differences in third-phase slopes between any of the
baseline strata. This supports the general conclusion
that if viral suppression can be maintained through
effective and uninterrupted HAART, a continued
pattern of CD4+ count improvement may occur in
most patients, irrespective of CD4+ count at HAART
initiation.
T h e r ea r es e v e r a lc a v e a t st ot h i so v e r a l lc o n c l u s i o n .
Although increases four years after starting HAART in
viral suppressors continued to be positive, they were
small. This provides support for current guidelines to
start HAART at higher CD4+ levels, before severe
immune suppression has occurred [1,2,30]. In addition,
our analysis indicates that a variety of other factors may
affect and modulate the CD4+ response curve, including
nadir CD4+ cell count, AIDS prior to HAART start and
pre-HAART duration of HIV infection.
Our analysis is consistent with other studies identify-
ing nadir CD4+ count as a predictor of CD4+ cell
response [31,32]. A lower nadir CD4+ count may reflect
a more profound disturbance of T-cell homeostasis,
with more severe immunological deficits that cannot be
reversed even with HAART-induced viral suppression
[33]. For example, in one analysis of response to immu-
nization in those with normal CD4+ counts and viral
suppression after more than a year, a lower CD4+ nadir
before HAART predicted poorer vaccination response
[34].
Our analysis also identified a clinical AIDS diagnosis
preceding HAART as a predictor of a poorer CD4+
response. This may be another reflection of functional
or other immune deficiencies in response to HIV infec-
tion that lead to a less robust immunologic recovery.
This finding supports current recommendations to initi-
ate HAART in all patients with a history of an AIDS-
defining illness, irrespective of their current CD4+ count
[1,2].
A major finding of this analysis was the strong nega-
tive effect of pre-HAART duration of HIV infection on
CD4+ cell response to HAART, even after controlling
for viral suppression, CD4+ count and other factors. A
previous study [14] also identified duration of infection
as a predictor of CD4+ response, but duration was
based upon time from the first recorded HIV test rather
than the entire estimated period of HIV infection, as
this analysis was able to do. Potential immunopatho-
genic explanations for why a longer time from HIV SC
to HAART start results in a more impaired capacity for
immunologic recovery include decreased CD4+ cell pro-
duction or excessive CD4+ cell destruction. For exam-
ple, it has been proposed that CD4+ T-cell
hyperactivation may persist even after HAART virologic
suppression, and that this results in greater apoptotic
cell death [32,33,35-37]. Our finding that both higher
baseline VLs and longer duration of pre-HAART infec-
tion were predictive of poorer immunologic response
suggests that long-standing high levels of viral replica-
tion may lead to persistent T-cell activation or other T-
cell dysfunction which cannot be fully reversed even
after HAART introduction.
This analysis has several potential limitations. First, by
definition those who were followed for >5 years repre-
sent “healthy survivors"; those who died or who dropped
out of the study because of illness soon after starting
HAART would not be captured in the third-phase
Table 4 Adjusted Covariate Estimates* for CD4+ Cell
Response Post-HAART for Viral Suppressors, U.S. Military
HIV Natural History Study
Covariate Estimate
(95% CI)
P-
value
Age at HAART start
Effect of 10 years older if < 40 years
old
6.3 (-9.6, 22.2) 0.44
Effect of 10 years older if > 40 years
old
- 5.1 (-23.9, 13.7) 0.59
Female (vs. Male) 57.2 (14.6, 99.8) 0.009
Race
Caucasian Reference
African American 9.2 (-7.3, 25.7) 0.27
Hispanic -10.8 (-38.6, 17.1) 0.45
Other 0.4 (-40.6, 41.4) 0.98
Clinical AIDS event prior to HAART start -32.7 (-66.4, 1.0) 0.057
Pre -HAART nadir CD4 count (cells/mm
3)
≤ 200 Reference
201-349 55.3 (20.7, 89.9) 0.002
350-499 135.4 (94.6, 176.2) <.001
≥ 500 195.1 (144.3,
245.8)
<.001
Baseline VL at HAART start (copies/ml) **
< 1000 8.5 (-21.6, 38.6) 0.58
1000-9999 -17.8 (-43.5, 7.9) 0.18
10,000-99,999 1.3 (-19.5, 22.2) 0.90
≥ 100,000 Reference
Years from SC to HAART initiation
≤ 1.5 Reference
> 1.5 to 4.0 -18.0 (-38.6, 2.6) 0.09
> 4.0 to 8.5 -27.7 (-52.0, -3.3) 0.03
≥ 8.5 -33.4 (-61.0, -5.8) 0.02
Year of HAART initiation
1995-1999 0.0 (-22.4, 22.4) 0.99
2000-2003 5.9 (-18.1, 29.9) 0.63
2004-2009 Reference
Any ART prior to HAART start 11.5 (-11.1, 34.0) 0.32
* Aside from baseline CD4+ count and time interval after HAART start.
** Analysis adjusted for those for whom VL was missing/unknown.
HAART = Highly active antiretroviral therapy; ART = Antiretroviral therapy;
VL = HIV Viral load; SC = Seroconversion;
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Page 8 of 11analysis. Although for the great majority of enrollees
death was uncommon, it was more common among
those in the lowest CD4+ cell strata. For example, a pre-
liminary analysis of mortality among those initiating
HAART at ≤200 CD4+ cells/mm
3 identified a 6-year
death rate of 18%, compared to rates of 3%-5% for those
initiating HAART at the higher CD4+ cell strata
(IDCRP, unpublished data). Although many patients are
still followed in the military health care system even if
they are no longer on active duty after an AIDS diagno-
sis, some patients with advanced disease may have sepa-
rated from the military system and had their health care
transferred to the Veteran’s Affairs or other health sys-
tems. However, even if such a healthy survivor effect did
occur, we do not believe that it significantly affected our
overall conclusions. Such an effect would most likely
occur in the lowest (≤200 cell) CD4+ stratum, and
among viral suppressors, the third-phase CD4+
increases we saw in this stratum were not significantly
different from those seen in the other baseline strata.
Nonetheless, the increased mortality seen in the lowest
group provides additional support for current guidelines
to start HAART before severe immune suppression has
occurred.
Second, in this observational study, the four baseline
strata were not randomized, and group differences may
be due to unmeasured confounding. We tried to limit
the extent of confounding by adjusting for many HIV-
related factors, as well as time-dependent covariates
including VL and HAART use. Analyzing our data in
different ways, including through several different
exploratory analyses, didn o tc h a n g eo u ro v e r a l l
conclusions.
Third, although we adjusted for different classes of
drug therapy at HAART initiation in our exploratory
sensitivity analyses, we did not present data on specific
A R Td r u g s .H o w e v e r ,t h i sw a sn o tt h ei n t e n to ft h i s
analysis. Even within a given antiretroviral class, there is
considerable variation depending on potency, drug-drug
interactions, use of ritonavir boosting for PIs, and multi-
ple other factors. Clinicians may select individual drugs
for a HAART regimen based on a variety of factors, and
information about the efficacy of specific ART drugs
and regimens is best obtained through randomized
trials.
Finally, this cohort is characterized by a number of
specific demographic and clinical factors, and results
may vary for other populations with different character-
istics. For example, 96% of our study sample was male,
and the median age was 36 years. Also, given the speci-
fic structured testing schedule in the military, it is likely
that many patients in this cohort were diagnosed with
HIV earlier than typically seen in clinical practice.
This analysis also has several strengths. First, in con-
trast to many other HIV cohort studies, we were able to
estimate SC date and time from HIV SC to HAART
start. The fact that this variable consistently emerged as
a significant predictor of CD4+ response supports the
importance of including this covariate in our analysis.
Second, follow-up in this analysis extended for some
patients out past 8 years, considerably longer than most
other observational studies. This analysis therefore pro-
vides an important contribution to the literature con-
cerning the long-term third-phase CD4+ response to
HAART, especially in those patients who maintain viro-
logic suppression.
Third, because HIV treatment in the military is free,
availability of care and access to therapy were not bar-
riers confounding our results. In fact, viral suppression
rates in this cohort have previously been reported as
approaching those in clinical trials [25].
Conclusions
Among HIV-infected persons who initiated HAART at
different CD4+ levels and who were followed in some
cases for over ten years, we identified a rapid followed
by a more gradual increase in CD4+ cells for the first
four years. After this time, among those who maintain
viral suppression, our results suggest that in all strata,
there will on average be a positive but small average
increase of about 12-16 cells per year. However, multi-
ple factors may influence this immunologic response,
including CD4+ nadir, a preceding AIDS diagnosis, and,
importantly, time from HIV infection to HAART start.
Our findings strongly support the conclusion that
immunologic response to HAART is maximized if treat-
ment is started with virally suppressive therapy as early
as possible.
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